CU 05
Alternative Names: CU-05Latest Information Update: 03 Jan 2024
At a glance
- Originator CURACLE
- Class Antineoplastics; Immunotherapies
- Mechanism of Action AMIGO2 protein antagonists; Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Lung cancer
Most Recent Events
- 03 Jan 2024 CU 05 is still in research phase for Lung cancer in South Korea (PO) (Curacle pipeline; January 2024)
- 28 Oct 2023 No recent reports of development identified for research development in Lung-cancer in South Korea (PO)
- 04 Oct 2019 CU 05 is available for licensing in World as of 04 Oct 2019. http://www.curacle.com/en/overview/